Works matching AU Lonial, Sagar

Results: 211
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12

    High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

    Published in:
    Cytometry. Part A, 2019, v. 95, n. 3, p. 279, doi. 10.1002/cyto.a.23693
    By:
    • Adams, Homer C.;
    • Stevenaert, Frederik;
    • Krejcik, Jakub;
    • Van der Borght, Koen;
    • Smets, Tina;
    • Bald, Jaime;
    • Abraham, Yann;
    • Ceulemans, Hugo;
    • Chiu, Christopher;
    • Vanhoof, Greet;
    • Usmani, Saad Z.;
    • Plesner, Torben;
    • Lonial, Sagar;
    • Nijhof, Inger;
    • Lokhorst, Henk M.;
    • Mutis, Tuna;
    • Donk, Niels W.C.J.;
    • Sasser, Amy Kate;
    • Casneuf, Tineke
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19

    P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
    By:
    • Lonial, Sagar;
    • Berdeja, Jesus G.;
    • Dimopoulos, Meletios-Athanasios;
    • Jagannath, Sundar;
    • Knop, Stefan;
    • Hang Quach;
    • Rodríguez-Otero, Paula;
    • Richardson, Paul G.;
    • Sorrell, April;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • Tuong Vi Nguyen;
    • Hong, Kevin;
    • Peluso, Teresa;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    20

    P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S149, doi. 10.1016/S2152-2650(21)02329-6
    By:
    • Lonial, Sagar;
    • Nooka, Ajay;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie;
    • Callander, Natalie S.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Esposti, Simona Degli;
    • Baron, January;
    • Doherty, Allison;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Prani Paka;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Farooq, Asim V.;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    21
    22
    23

    OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02101-7
    By:
    • Anderson, Jr., Larry D.;
    • Nina Shah;
    • Jagannath, Sundar;
    • Berdeja, Jesus G.;
    • Lonial, Sagar;
    • Raje, Noopur;
    • Siegel, David S.;
    • Yi Lin;
    • Moreau, Philippe;
    • Yakoub-Agha, Ibrahim;
    • Delforge, Michel;
    • Einsele, Hermann;
    • Goldschmidt, Hartmut;
    • Weisel, Katja;
    • Cavo, Michele;
    • Reece, Donna E.;
    • Rambaldi, Alessandro;
    • Truppel-Hartmann, Anna;
    • Patel, Payal;
    • Liping Huang
    Publication type:
    Article
    24

    OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
    By:
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Popat, Rakesh;
    • Stadtmauer, Edward A.;
    • Larsen, Jeremy T.;
    • Oriol, A.;
    • Knop, Stefan;
    • Jagannath, Sundar;
    • Cook, Gordon;
    • Badros, Ashraf Z.;
    • Rodríguez-Otero, Paula;
    • Siegel, David S.;
    • Tuong Vi Nguyen;
    • Micco, Antonia Di;
    • Amin, Alpesh;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    25
    26

    MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S419, doi. 10.1016/S2152-2650(21)01940-6
    By:
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Esposti, Simona Degli;
    • Baron, January;
    • Doherty, Allison;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Paka, Prani;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Farooq, Asim V.;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    27

    ABCL-378: Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S396, doi. 10.1016/S2152-2650(21)01898-X
    By:
    • Santapuram, Pranav;
    • Rupji, Manali;
    • Graiser, Michael;
    • Waller, Edmund;
    • Blum, Kristie;
    • Allen, Pamela;
    • Koff, Jean;
    • Heffner, Leonard;
    • Lechowicz, Mary;
    • Lonial, Sagar;
    • Kaufman, Jonathan;
    • Dhopadkar, Madhav;
    • Nooka, Ajay;
    • Blum, William;
    • Klisovic, Rebecca;
    • Joseph, Nisha;
    • Gupta, Vikas;
    • Langston, Amelia;
    • Cohen, Jonathan
    Publication type:
    Article
    28

    Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01576-7
    By:
    • Lonial, Sagar;
    • Nooka, Ajay K.;
    • Thulasi, Praneetha;
    • Badros, Ashraf Z.;
    • Jeng, Bennie H.;
    • Callander, Natalie S.;
    • Sborov, Douglas;
    • Zaugg, Brian E.;
    • Popat, Rakesh;
    • Esposti, Simona Degli;
    • Baron, January;
    • Doherty, Allison;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Paka, Prani;
    • Piontek, Trisha;
    • Gupta, Ira;
    • Farooq, Asim V.;
    • Jakubowiak, Andrzej
    Publication type:
    Article
    29

    Poster: ABCL-378: Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S240, doi. 10.1016/S2152-2650(21)01509-3
    By:
    • Santapuram, Pranav;
    • Rupji, Manali;
    • Graiser, Michael;
    • Waller, Edmund;
    • Blum, Kristie;
    • Allen, Pamela;
    • Koff, Jean;
    • Heffner, Leonard;
    • Lechowicz, Mary;
    • Lonial, Sagar;
    • Kaufman, Jonathan;
    • Dhopadkar, Madhav;
    • Nooka, Ajay;
    • Blum, William;
    • Klisovic, Rebecca;
    • Joseph, Nisha;
    • Gupta, Vikas;
    • Langston, Amelia;
    • Cohen, Jonathan
    Publication type:
    Article
    30
    31
    32
    33
    34

    Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting.

    Published in:
    Life Science Alliance, 2022, v. 5, n. 3, p. 1, doi. 10.26508/lsa.202101285
    By:
    • Joyner, Chester J.;
    • Ley, Ariel M.;
    • Nguyen, Doan C.;
    • Ali, Mohammad;
    • Corrado, Alessia;
    • Tipton, Christopher;
    • Scharer, Christopher D.;
    • Mi, Tian;
    • Woodruff, Matthew C.;
    • Hom, Jennifer;
    • Boss, Jeremy M.;
    • Duan, Meixue;
    • Gibson, Greg;
    • Roberts, Danielle;
    • Andrews, Joel;
    • Lonial, Sagar;
    • Sanz, Inaki;
    • Eun-Hyung Lee, F.
    Publication type:
    Article
    35

    Transposon DNA sequences facilitate the tissue-specific gene transfer of circulating tumor DNA between human cells.

    Published in:
    Nucleic Acids Research, 2024, v. 52, n. 13, p. 7539, doi. 10.1093/nar/gkae427
    By:
    • Cinar, Munevver;
    • Martinez-Medina, Lourdes;
    • Puvvula, Pavan K;
    • Arakelyan, Arsen;
    • Vardarajan, Badri N;
    • Anthony, Neil;
    • Nagaraju, Ganji P;
    • Park, Dongkyoo;
    • Feng, Lei;
    • Sheff, Faith;
    • Mosunjac, Marina;
    • Saxe, Debra;
    • Flygare, Steven;
    • Alese, Olatunji B;
    • Kaufman, Jonathan L;
    • Lonial, Sagar;
    • Sarmiento, Juan M;
    • Lossos, Izidore S;
    • Vertino, Paula M;
    • Lopez, Jose A
    Publication type:
    Article
    36
    37
    38

    Antibody Treatment in Multiple Myeloma.

    Published in:
    Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 3, p. 166
    By:
    • Maples, Kathryn T.;
    • Johnson, Catherine;
    • Lonial, Sagar
    Publication type:
    Article
    39
    40
    41
    42

    Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation.

    Published in:
    Molecular & Cellular Biology, 2009, v. 29, n. 8, p. 2105, doi. 10.1128/MCB.00998-08
    By:
    • Kang, Sumin;
    • Elf, Shannon;
    • Shaozhong Dong;
    • Hitosugi, Taro;
    • Lythgoe, Katherine;
    • Guo, Ailan;
    • Hong Ruan;
    • Lonial, Sagar;
    • Khoury, Hanna J.;
    • Williams, Ifor R.;
    • Lee, Benjamin H.;
    • Roesel, Johannes L.;
    • Gerard Karsenty;
    • Hanauer, André;
    • Taunton, Jack;
    • Boggon, Titus J.;
    • Ting-Lei Gu;
    • Jing Chen
    Publication type:
    Article
    43
    44
    45
    46
    47

    Deacetylase inhibitors: an advance in myeloma therapy?

    Published in:
    Expert Review of Hematology, 2017, v. 10, n. 3, p. 229, doi. 10.1080/17474086.2017.1280388
    By:
    • Laubach, Jacob P.;
    • San-Miguel, Jesus F.;
    • Hungria, Vania;
    • Hou, Jian;
    • Moreau, Philippe;
    • Lonial, Sagar;
    • Lee, Jae Hoon;
    • Einsele, Hermann;
    • Alsina, Melissa;
    • Richardson, Paul G.
    Publication type:
    Article
    48
    49
    50